Human herpesviruses 6, 7 and 8 in solid organ transplant recipients

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1% of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most commonmanifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV- 6 and HHV-7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV-8 is an oncogenic gamma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV- 8. Reduction in immunosuppression is the first line treatment of HHV-8 infection. Other alternatives for treatment, especially for HHV-8 diseases not responsive to immuno-minimization strategies, are surgery and chemotherapy. Sirolimus has been shown to be a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV-8 infection is being investigated.

Original languageEnglish (US)
Pages (from-to)67-78
Number of pages12
JournalAmerican Journal of Transplantation
Issue numberSUPPL. 3
StatePublished - 2013


  • Human herpesvirus 6
  • Human herpesvirus 7
  • Human herpesvirus 8
  • Kaposi's sarcoma
  • Roseola infantum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)


Dive into the research topics of 'Human herpesviruses 6, 7 and 8 in solid organ transplant recipients'. Together they form a unique fingerprint.

Cite this